<DOC>
	<DOC>NCT02871778</DOC>
	<brief_summary>To evaluate the safety and efficacy of treatment with VX-371, and the effect of VX-371 on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).</brief_summary>
	<brief_title>Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Ciliary Motility Disorders</mesh_term>
	<mesh_term>Kartagener Syndrome</mesh_term>
	<criteria>Confirmed diagnosis of PCD Subjects with percent predicted FEV1 of â‰¥40 to &lt;90 percentage points Nonsmoker for at least 90 days prior to the Screening Visit and less than a 5 packyear lifetime history of smoking Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1 If currently using daily inhaled HS, must be able to discontinue its use for the duration of the study. If taking daily chronic or chronic cycling antibiotics, has been on a consistent regimen for at least 4 months prior to the Screening Visit. Clinically stable (as deemed by the investigator) for at least 14 days prior to the Screening Visit Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit. Subjects of childbearing potential and who are sexually active must meet the contraception requirements. Diagnosis of CF based on results of sweat chloride or nasal transepithelial potential difference (NPD) tests or presence of 2 CFcausing genetic mutations in CFTR gene. History of any organ transplantation or lung resection or chest wall surgery of such severity that it has an impact on pulmonary function. Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome). Inability to withhold shortacting bronchodilator use for 4 hours prior to clinic visit. Use of diuretics (including amiloride) or reninangiotensin antihypertensive drugs Symptoms of acute upper or lower respiratory tract infection, acute pulmonary exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus disease within 14 days before Day 1 (topical otic antibiotics allowed). History of significant intolerance to inhaled HS Pregnant and/or nursing females Any clinically significant laboratory abnormalities History of chronic B. cepacia complex or M. abscessus or M. avium Surgery that required general anesthesia and hospitalization within 3 months of Day 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>